Literature DB >> 17565587

Antiviral action of interferon-alpha against hepatitis C virus replicon and its modulation by interferon-gamma and interleukin-8.

Yintang Jia1, Lai Wei, Dong Jiang, Jianghua Wang, Xu Cong, Ran Fei.   

Abstract

BACKGROUND AND AIM: Interferon-alpha (IFN-alpha) based therapy is the main treatment used to control hepatitis C virus (HCV) infection. The aim of this study was to understand the mechanisms of IFN-alpha inhibition of HCV replication and the resistance of HCV to IFN-alpha therapy, and improve the efficiency of HCV treatment.
METHODS: The inhibitory effects of IFN-alpha on a HCV replicon system were examined and the potential regulatory effects of interferon-gamma (IFN-gamma) and interleukin-8 (IL-8) on the antiviral actions of IFN-alpha were also investigated in this report.
RESULTS: The results showed that IFN-alpha can effectively inhibit the replication of HCV replicon. Pretreatment of HCV replicon cells with IFN-gamma could significantly potentiate the inhibitory effects of IFN-alpha on the HCV replicon. Direct addition of IL-8 to the culture medium of HCV replicon cells could partially rescue the HCV replicon from the inhibition of IFN-alpha, which may be the result of IL-8 down-regulation of interferon-stimulated genes.
CONCLUSION: Our study demonstrated that IFN-gamma has synergistic antiviral effects with IFN-alpha; whereas IL-8 can attenuate the anti-HCV actions of IFN-alpha and is associated with HCV resistance to interferon-alpha therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17565587     DOI: 10.1111/j.1440-1746.2007.04957.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  10 in total

1.  Geranylgeranylacetone has anti-hepatitis C virus activity via activation of mTOR in human hepatoma cells.

Authors:  Shigeyuki Takeshita; Tatsuki Ichikawa; Naota Taura; Hisamitsu Miyaaki; Toshihisa Matsuzaki; Masashi Otani; Toru Muraoka; Motohisa Akiyama; Satoshi Miuma; Eisuke Ozawa; Masanori Ikeda; Nobuyuki Kato; Hajime Isomoto; Fuminao Takeshima; Kazuhiko Nakao
Journal:  J Gastroenterol       Date:  2011-10-25       Impact factor: 7.527

Review 2.  Between Scylla and Charybdis: the role of the human immune system in the pathogenesis of hepatitis C.

Authors:  Ulrich Spengler; Hans Dieter Nischalke; Jacob Nattermann; Christian P Strassburg
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

3.  Promiscuous prediction and conservancy analysis of CTL binding epitopes of HCV 3a viral proteome from Punjab Pakistan: an in silico approach.

Authors:  Abida Shehzadi; Shahid Ur Rehman; Muhammad Idrees
Journal:  Virol J       Date:  2011-02-08       Impact factor: 4.099

4.  Interferon-α improves phosphoantigen-induced Vγ9Vδ2 T-cells interferon-γ production during chronic HCV infection.

Authors:  Eleonora Cimini; Cécile Bonnafous; Veronica Bordoni; Eleonora Lalle; Helene Sicard; Alessandra Sacchi; Giulia Berno; Cristiana Gioia; Gianpiero D'Offizi; Ubaldo Visco Comandini; Chrysoula Vlassi; Maria Rosaria Capobianchi; Federico Martini; Chiara Agrati
Journal:  PLoS One       Date:  2012-05-22       Impact factor: 3.240

5.  Spontaneous hepatitis C viral clearance and hepatitis C chronic infection are associated with distinct cytokine profiles in Mexican patients.

Authors:  Nora A Fierro; Karina González-Aldaco; Rafael Torres-Valadez; Maria E Trujillo-Trujillo; Sonia Roman; Jorge L Trujillo-Ochoa; Arturo Panduro
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-04-01       Impact factor: 2.743

6.  Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study.

Authors:  Willem P Brouwer; Henry L Y Chan; Pietro Lampertico; Jinlin Hou; Pisit Tangkijvanich; Hendrik W Reesink; Wenhong Zhang; Alessandra Mangia; Tawesak Tanwandee; Giuseppe Montalto; Kris Simon; Necati Ormeci; Liang Chen; Fehmi Tabak; Fulya Gunsar; Robert Flisiak; Peter Ferenci; Meral Akdogan; Filiz Akyuz; Nattiya Hirankarn; Louis Jansen; Vincent Wai-Sun Wong; Roberta Soffredini; Xieer Liang; Shalom Chen; Zwier M A Groothuismink; Rosanna Santoro; Jerzy Jaroszewicz; Resat Ozaras; Karin Kozbial; Mayur Brahmania; Qing Xie; Watcharasak Chotiyaputta; Qi Xun; Monika Pazgan-Simon; Erkin Oztas; Elke Verhey; Noé R Montanari; Jian Sun; Bettina E Hansen; Andre Boonstra; Harry L A Janssen
Journal:  Clin Infect Dis       Date:  2019-11-13       Impact factor: 9.079

7.  Hepatitis C virus infection of a thyroid cell line: implications for pathogenesis of hepatitis C virus and thyroiditis.

Authors:  Jason T Blackard; Ling Kong; Amanda K Huber; Yaron Tomer
Journal:  Thyroid       Date:  2013-06-21       Impact factor: 6.568

8.  HIV infection of hepatocytes results in a modest increase in hepatitis C virus expression in vitro.

Authors:  Ling Kong; Jeffrey A Welge; Eleanor A Powell; Jason T Blackard
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

9.  The correlation between pretreatment cytokine expression patterns in peripheral blood mononuclear cells with chronic hepatitis C outcome.

Authors:  Joanna Jabłońska; Tomasz Pawłowski; Tomasz Laskus; Małgorzata Zalewska; Małgorzata Inglot; Sylwia Osowska; Karol Perlejewski; Iwona Bukowska-Ośko; Kamila Caraballo Cortes; Agnieszka Pawełczyk; Piotr Ząbek; Marek Radkowski
Journal:  BMC Infect Dis       Date:  2015-12-04       Impact factor: 3.090

Review 10.  Recent advances in the anti-HCV mechanisms of interferon.

Authors:  Menghao Huang; Jian-Dong Jiang; Zonggen Peng
Journal:  Acta Pharm Sin B       Date:  2014-07-14       Impact factor: 11.413

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.